Announcement from the University of Pennsylvania for a clinical trial for hemangiosarcoma:

Further Evaluation of the Benefits of a Traditional Chinese Medicine Supplement for Dogs with Splenic Hemangiosarcoma

Dec 6, 2013
In a previous study conducted here at PennVet, the mushroom supplement I’m-Yunity® significantly increased survival time in dogs with splenic hemangiosarcoma. I’m-Yunity® extract effectively delivers the standardized ingredient polysaccharopeptide (PSP) which can only be isolated from the Coriolus Versicolor mushroom.

In this new trial, we will be comparing I’m-Yunity’s® effect on survival time and quality of life to the standard chemotherapy treatment.

Dogs will randomly be chosen to receive either chemotherapy, I’m-Yunity® treatment, or both concurrently, and owners will not know to which treatment group their dog was assigned. Dogs enrolled in this study will have 11 weekly visits, followed by monthly follow-up visits until the end of their life.

Eligibility:

  • Diagnosis of hemangiosarcoma following splenectomy.
  • At least 4 kg.
  • Not currently undergoing treatment for cancer.
  • No other significant health concerns that are an immediate threat to life.
  • Ability to administer oral medication (pills) to your dog.

Please contact the VCIC at 215-573-0302 or vcic@vet.upenn.edu for more information about this study.

Chinese Medicine Holdings, the makers of I’m-Yunity supplement, is the sponsor of both studies,  but both studies were designed by the Penn clinical epidemiologist, who is also the principle investigator.